Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Lupini, Laura ^a   Bassi, Cristian ^a   Mlcochova, Jitka ^b   Musa, Gentian ^a   Russo, Marta ^a   Vychytilova Faltejskova, Petra ^b   Svoboda, Marek ^b,c   Sabbioni, Silvia ^a   Nemecek, Radim ^c   Slaby, Ondrej ^b,c   Negrini, Massimo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b CENTRAL EUROPEAN INSTITUTE OF TECHNOLOGY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Colorectal cancer; Gene mutations; Next generation sequencing; Resistance to anti EGFR antibodies

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMAD4 PROTEIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANTIEPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY BASED THERAPY; ARTICLE; BRAF GENE; CLINICAL ARTICLE; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; GENE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; KRAS GENE; MALE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NRAS GENE; ONCOGENE RAS; PHENOTYPE; PI3KCA GENE; PREDICTION; PROTO ONCOGENE; PTEN GENE; TREATMENT RESPONSE; WILD TYPE; AGED; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; GENETICS; MIDDLE AGED; PREDICTIVE VALUE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84946494938     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1752-5     Document Type: Article

References (36)

1. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7):1254-61.
2. Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki C, Scorilas A, et al. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. Clin Cancer Res. 2014;20(11):2933-46.
3. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532-6.
4. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer. 2010;103(12):1765-72.
5. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer. 2013.
6. Benson 3rd AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014;12(7):1028-59.
7. Network. CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-7.
8. Ion Ampliseq Designer. [ https://www.ampliseq.com/browse.action ].
9. Wong SQ, Li J, Tan AY, Vedururu R, Pang JM, Do H, et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics. 2014;7:23.
10. NCBI dbSNP - Short Genetic Variations. [ http://www.ncbi.nlm.nih.gov/projects/SNP/ ].
11. Cosmic: catalogue of somatic mutations in cancer. [ http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ ].
12. cBio Portal for Cancer Genomics. [ http://www.cbioportal.org/public-portal/ ].
13. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. [ http://www.openbioinformatics.org/annovar/ ].
14. Mutation Assessor.org - functional impact of protein mutations. [ http://mutationassessor.org/ ].
15. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382-4.
16. Dono M, Massucco C, Chiara S, Sonaglio C, Mora M, Truini A, et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Mol Med. 2012;18:1519-26.
17. Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann Oncol. 2014;25(9):1756-61.
18. Morelli MP, Kopetz S. Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol. 2012;30(29):3565-7.
19. Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. Clin Cancer Res. 2013;19(15):4104-13.
20. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471(7336):110-4.
21. Wang Z, Fukushima H, Gao D, Inuzuka H, Wan L, Lau AW, et al. The two faces of FBW7 in cancer drug resistance. Bioessays. 2011;33(11):851-9.
22. Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, Sato T, et al. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer J International du cancer. 2010;126(8):1828-37.
23. Zhao D, Zheng HQ, Zhou Z, Chen C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 2010;70(11):4728-38.
24. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat. 2012;134(1):333-43.
25. Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, et al. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med. 2013;210(8):1545-57.
26. King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P, et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013;153(7):1552-66.
27. Falisi E, Novella E, Visco C, Guercini N, Maura F, Giaretta I, et al. B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. Hematol Oncol. 2014;32(1):22-30.
28. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10(1):29-46.
29. Minella AC, Welcker M, Clurman BE. Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci U S A. 2005;102(27):9649-54.
30. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004;23(10):2116-25.
31. Hoeck JD, Jandke A, Blake SM, Nye E, Spencer-Dene B, Brandner S, et al. Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat Neurosci. 2010;13(11):1365-72.
32. Thompson BJ, Jankovic V, Gao J, Buonamici S, Vest A, Lee JM, et al. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med. 2008;205(6):1395-408.
33. Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 2009;69(23):8967-76.
34. Sancho R, Jandke A, Davis H, Diefenbacher ME, Tomlinson I, Behrens A. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology. 2010;139(3):929-41.
35. Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature. 2011;476(7359):163-9.
36. ArrayExpress. [ https://www.ebi.ac.uk/arrayexpress/ ].